Details of Disease

General Information of Disease (ID: DISZX24B)

• Disease Name: Secondary hyperparathyroidism
• Synonyms: secondary hyperparathyroidism NOS; secondary hyperparathyroidism; secondary hyperparathyroidism (disease)
• Disease Class: 5A51: Hyper-parathyroidism
• Definition: Overproduction of parathyroid hormone in response to influence external to the parathyroid glands.
• Disease Hierarchy:
  DIS4FVAT: Hyperparathyroidism
  DISZX24B: Secondary hyperparathyroidism
• ICD Code:
  ICD-11: ICD-11: 5A51.1
  ICD-10: ICD-10: E21.1
  Expand ICD-11: '5A51.1
  Expand ICD-10: 'E21.1
• Disease Identifiers:
  MONDO ID: MONDO_0006964
  MESH ID: D006962
  UMLS CUI: C0020503
  MedGen ID: 9368
  HPO ID: HP:0000867
  SNOMED CT ID: 91478007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Etelcalcetide	DMHP9BL	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 9 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CYP24A1	TT82UI1	Limited	Biomarker	[2]
DMPK	TTZQTY2	Limited	Altered Expression	[3]
NR4A3	TTJQB49	Limited	Biomarker	[4]
SOST	TTYRO4F	Limited	Biomarker	[5]
ABCG2	TTIMJ02	Strong	Altered Expression	[6]
CEBPB	TTUI35N	Strong	Biomarker	[7]
CRP	TTWRN6M	Strong	Biomarker	[8]
PIN1	TTJNTSI	Strong	Genetic Variation	[9]
ALPL	TTMR5UV	Definitive	Biomarker	[10]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACP5	DESITDW	Definitive	Biomarker	[10]
CYP27B1	DE3FYEM	Definitive	Biomarker	[11]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MAFB	OTH2N3T8	Limited	Biomarker	[12]
OSCP1	OTZ4IFGJ	Limited	Biomarker	[4]
AMELX	OTIN26MM	moderate	Biomarker	[13]
CDH17	OT9EV2XK	Strong	Biomarker	[14]
KL	OTD4VWU6	Strong	Altered Expression	[15]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] Recent developments for introducing a hexafluoroisopropanol unit into the Vitamin D side chain.J Steroid Biochem Mol Biol. 2018 Mar;177:250-254. doi: 10.1016/j.jsbmb.2017.07.008. Epub 2017 Jul 14.
• [3] Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.Bioorg Med Chem Lett. 2018 Jun 15;28(11):2055-2060. doi: 10.1016/j.bmcl.2018.04.055. Epub 2018 Apr 24.
• [4] Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients.Pediatr Nephrol. 2017 Jul;32(7):1103-1108. doi: 10.1007/s00467-017-3675-7. Epub 2017 Apr 27.
• [5] Sclerostin deficiency modifies the development of CKD-MBD in mice.Bone. 2018 Feb;107:115-123. doi: 10.1016/j.bone.2017.11.015. Epub 2017 Nov 21.
• [6] Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.Kidney Int. 2017 Mar;91(3):658-670. doi: 10.1016/j.kint.2016.09.041. Epub 2016 Dec 15.
• [7] The induction of C/EBP contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.Nephrol Dial Transplant. 2015 Mar;30(3):423-33. doi: 10.1093/ndt/gfu311. Epub 2014 Oct 7.
• [8] Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2011 Mar;223(3):153-9. doi: 10.1620/tjem.223.153.
• [9] Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels.Ren Fail. 2017 Nov;39(1):159-165. doi: 10.1080/0886022X.2016.1256310. Epub 2016 Nov 23.
• [10] Parathyroidectomy leads to decreased blood lead levels in patients with refractory secondary hyperparathyroidism.Bone. 2012 May;50(5):1032-8. doi: 10.1016/j.bone.2012.02.011. Epub 2012 Feb 21.
• [11] Absence of Calcitriol Causes Increased Lactational Bone Loss and Lower Milk Calcium but Does Not Impair Post-lactation Bone Recovery in Cyp27b1 Null Mice.J Bone Miner Res. 2018 Jan;33(1):16-26. doi: 10.1002/jbmr.3217. Epub 2017 Aug 2.
• [12] Transcription factor MafB may play an important role in secondary hyperparathyroidism.Kidney Int. 2018 Jan;93(1):54-68. doi: 10.1016/j.kint.2017.06.023. Epub 2017 Sep 28.
• [13] Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):43-53. doi: 10.1007/s10928-016-9503-z. Epub 2017 Jan 6.
• [14] Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.J Clin Endocrinol Metab. 2018 Jun 1;103(6):2189-2198. doi: 10.1210/jc.2017-02506.
• [15] Changes in serum FGF23 and Klotho levels and calcification scores of the abdominal aorta after parathyroidectomy for secondary hyperparathyroidism.Am J Surg. 2019 Sep;218(3):609-612. doi: 10.1016/j.amjsurg.2018.12.026. Epub 2018 Dec 18.